Literature DB >> 9150155

Study of a single BRCA2 mutation with high carrier frequency in a small population.

S Thorlacius1, S Sigurdsson, H Bjarnadottir, G Olafsdottir, J G Jonasson, L Tryggvadottir, H Tulinius, J E Eyfjörd.   

Abstract

Germ-line changes in the cancer-predisposition gene BRCA2 are found in a small proportion of breast cancers. Mutations in the BRCA2 gene have been studied mainly in families with high risk of breast cancer in females, and male breast cancer also has been associated with BRCA2 mutations. The importance of germ-line BRCA2 mutations in individuals without a family history of breast cancer is unknown. The same BRCA2 mutation has been found in 16/21 Icelandic breast cancer families, indicating a founder effect. We determined the frequency of this mutation, 999del5, in 1,182 Icelanders, comprising 520 randomly selected individuals from the population and a series of 632 female breast cancer patients (61.4% of patients diagnosed during the study period) and all male breast cancer patients diagnosed during the past 40 years. We detected the 999del5 germ-line mutation in 0.6% of the population, in 7.7% of female breast cancer patients, and in 40% of males with breast cancer. The mutation was strongly associated with onset of female breast cancer at age <50 years, but its penetrance and expression are varied. A number of cancers other than breast cancer were found to be increased in relatives of mutation carriers, including those with prostate and pancreatic cancer. Furthermore, germ-line BRCA2 mutation can be present without a strong family history of breast cancer. Comparison of the age at onset for mother/daughter pairs with the 999del5 mutation and breast cancer indicates that age at onset is decreasing in the younger generation. Increase in breast cancer incidence and lower age at onset suggest a possible contributing environmental factor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150155      PMCID: PMC1712443     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  17 in total

Review 1.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.

Authors:  M C Pike; D V Spicer; L Dahmoush; M F Press
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

2.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Authors:  R Wooster; S L Neuhausen; J Mangion; Y Quirk; D Ford; N Collins; K Nguyen; S Seal; T Tran; D Averill
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

3.  Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer.

Authors:  R B Barkardóttir; A Arason; V Egilsson; J Gudmundsson; A Jónasdóttir; G Jóhannesdóttir
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

4.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

Authors:  M Schutte; L T da Costa; S A Hahn; C Moskaluk; A T Hoque; E Rozenblum; C L Weinstein; M Bittner; P S Meltzer; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

5.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

6.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

7.  Familial and sporadic breast cancer cases in Iceland: a comparison related to ABO blood groups and risk of bilateral breast cancer.

Authors:  L Tryggvadottir; H Tulinius; J M Robertson
Journal:  Int J Cancer       Date:  1988-10-15       Impact factor: 7.396

8.  Genetic changes in breast carcinomas in an Icelandic population.

Authors:  J E Eyfjörd; S Thorlacius
Journal:  Pharmacogenetics       Date:  1992-12

9.  Linkage to BRCA2 region in hereditary male breast cancer.

Authors:  S Thorlacius; L Tryggvadottir; G H Olafsdottir; J G Jonasson; H M Ogmundsdottir; H Tulinius; J E Eyfjord
Journal:  Lancet       Date:  1995-08-26       Impact factor: 79.321

Review 10.  The genetics of breast and ovarian cancer.

Authors:  D Ford; D F Easton
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  72 in total

1.  BRCA1 and BRCA2 testing: weighing the demand against the benefits.

Authors:  P Devilee
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 2.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

3.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.

Authors:  Yuan Chun Ding; Linda Steele; Chih-Jen Kuan; Scott Greilac; Susan L Neuhausen
Journal:  Breast Cancer Res Treat       Date:  2010-10-07       Impact factor: 4.872

4.  BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity.

Authors:  Abida Juwle; Dhananjaya Saranath
Journal:  Med Oncol       Date:  2012-07-03       Impact factor: 3.064

5.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

6.  Population genetics of BRCA1 and BRCA2.

Authors:  C I Szabo; M C King
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  Old meets new: identifying founder mutations in genetic disease.

Authors:  Jane A Evans
Journal:  CMAJ       Date:  2015-01-19       Impact factor: 8.262

Review 8.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.

Authors:  Gabriel Chodick; Jeffery P Struewing; Elaine Ron; Joni L Rutter; Jose Iscovich
Journal:  Eur J Med Genet       Date:  2007-11-22       Impact factor: 2.708

10.  BRCA1 and BRCA2 mutations in Scotland and Northern Ireland.

Authors: 
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.